FAVLYXA - (250MG/10ML (25MG/ML); SOLUTION)

Generic Name	FLUOROURACIL	**Innovator**	None
Dosage	250MG/10ML (25MG/ML); SOLUTION	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	FAVLYXA is a nucleoside metabolic inhibitor indicated for the treatment of patients with: •Adenocarcinoma of the Colon and Rectum •Adenocarcinoma of the Breast •Gastric Adenocarcinoma •Pancreatic Adenocarcinoma		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.